LncRNA UCA1 in anti-cancer drug resistance

// Haohao Wang 1, 2 , Zhonghai Guan 1 , Kuifeng He 1, 2 , Jiong Qian 1 , Jiang Cao 3 and Lisong Teng 1, 2 1 Cancer Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, P.R. China 2 Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, Hangzhou, Zhejiang, P.R. China 3 Clinical Research Center, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, P.R. China Correspondence to: Lisong Teng, email: [email protected] Keywords: long non-coding RNA, UCA1, chemoresistance, cancer Received: February 28, 2017      Accepted: May 22, 2017      Published: June 02, 2017 ABSTRACT The pivotal role of the long non-coding RNA (lncRNA) urothelial carcinoma associated 1 (UCA1) in anti-cancer drug resistance has been confirmed in many cancers. Overexpression of lncRNA UCA1 correlates with resistance to chemotherapeutics such as cisplatin, gemcitabine, 5-FU, tamoxifen, imatinib and EGFR-TKIs, whereas lncRNA UCA1 knockdown restores drug sensitivity. These studies highlight the potential of lncRNA UCA1 as a diagnostic and prognostic biomarker, and a therapeutic target in malignant tumors. In this review, we address the role of lncRNA UCA1 in anti-cancer drug resistance and discuss its potential in future clinical applications.

Hali tarjima qilinmagan